Press Release - January 20, 2016
Heidelberg, Germany, January 20, 2016 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that the Company will host a live webcast in conjunction with its Hodgkin’s Lymphoma Day with key opinion leaders on Tuesday, January 26, 2016 in New York City. This event for institutional investors will focus on Affimed’s leadership in the application of NK-cell biology using its NK-cell-engaging TandAb, AFM13. The webcast of the presentations and Q&A will begin at 10 a.m. EST and is scheduled to conclude at 1:30 p.m. EST.
The discussion will be moderated by Affimed’s Chief Medical Officer, Jens-Peter Marschner, M.D., and the Company’s Chief Scientific Officer, Martin Treder, Ph.D., will also be available to discuss AFM13, the Company’s lead candidate currently in a Phase 2a study for the treatment of Hodgkin’s lymphoma.
The Hodgkin’s Lymphoma KOL Day will include presentations by four world-renowned experts in the fields of Hodgkin’s lymphoma, immunotherapy and NK-cell biology.
Dr. Engert will discuss the current understanding of Hodgkin’s lymphoma, the available treatments and the existing need for better therapies. Dr. Evens will address the challenges and opportunities of future treatment options for Hodgkin’s lymphoma, including immunotherapies. Dr. Caligiuri will focus on NK-cells and their modulation by the PD-1/PD-L1 axis. Dr. Kohrt will discuss the rationale for the use of combination therapies in cancer based on his preclinical work with AFM13.
A link to the live webcast may be accessed by visiting the “Investors”section of the Affimed website, at www.affimed.com. A replay of the webcast will be available on Affimed’s website shortly after the event and will be archived on the Affimed website for 30 days following the call. Analysts and qualified investors who would like to register to attend or learn more about the event should contact affimedRSVP@troutgroup.com.
Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
Caroline Stewart, Head IR
Phone: +1 347 394 6793